Immunophotonics is excited to share that Dr. Theresa Visarius, VP Business Development will be attending the LSX World Congress Europe in London, April 28-30. This is a great opportunity to meet Theresa personally and hear how our phase 2 clinical stage asset, IP-001, provides a unique solution to combat solid tumor cancers and prevent their recurrence.